• Citer

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.

par Moretti, Erica;Desmedt, Christine ;Biagioni, Chiara;Regan, Meredith M;Oakman, Catherine;Larsimont, Denis ;Galardi, Francesca;Piccart-Gebhart, Martine ;Sotiriou, Christos ;Rimm, David D.L.;Di Leo, Angelo
Référence Future oncology, 9, 10, page (1477-1487)
Publication Publié, 2013-10

Article révisé par les pairs

• Détails
• Contenu

Titre:	TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.
Auteur:	Moretti, Erica; Desmedt, Christine; Biagioni, Chiara; Regan, Meredith M; Oakman, Catherine; Larsimont, Denis; Galardi, Francesca; Piccart-Gebhart, Martine; Sotiriou, Christos; Rimm, David D.L.; Di Leo, Angelo
Informations sur la publication:	Future oncology, 9, 10, page (1477-1487)
Statut de publication:	Publié, 2013-10
Sujet CREF:	Cancérologie
	Médecine pathologie humaine
	Sciences bio-médicales et agricoles
Mots-clés:	anthracyclines
	biomarker
	breast cancer
	quantitative immunofluorescence
	TOP2A
MeSH keywords:	Antigens, Neoplasm -- genetics -- metabolism
	Antineoplastic Agents -- therapeutic use
	Breast Neoplasms -- drug therapy -- metabolism -- mortality
	Cell Nucleus -- metabolism
	Cytoplasm -- metabolism
	DNA Topoisomerases, Type II -- genetics -- metabolism
	DNA-Binding Proteins -- genetics -- metabolism
	Epirubicin -- therapeutic use
	Female
	Humans
	Immunohistochemistry
	Neoadjuvant Therapy
	Prognosis
	Protein Transport
	Topoisomerase II Inhibitors -- therapeutic use
Note générale:	Journal Article
	Research Support, Non-U.S. Gov't
	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1479-6694
	info:doi/10.2217/fon.13.103
	info:scp/84885635917
	info:pmid/24106899